What government programs may be cut in Carney's spending review

Departmental plans under Carney’s spending review show material program rollbacks across major portfolios: ESDC cuts include a $20M reduction to Canada Service Corps, Future Skills trimmed by an additional $15M, and Apprenticeship Strategy falling to $113M by 2028-29 (with a $42M blip higher in 2026-27). Global Affairs will pare foreign aid and multilateral contributions (WHO -$3M/yr, OECD -$3M/yr, Pan American Health -$2M/yr; Commonwealth Youth down from $1.15M to $42,250), while ISED scales back Horizon Europe funding from $63M to $18M in 2028-29. Health Canada programs face steep declines (Oral Health Access Fund from $100M to $33.9M then to $21.8M and ultimately $9.75M; Substance Use & Addictions from $122.1M to $36.5M by 2028-29); these are departmental projections and not final appropriations, but they signal meaningful fiscal tightening for social, research and international aid budgets.

Analysis

The spending review rebalances marginal dollars away from social, health and research programs toward defence and core government priorities — a cash-flow shift that plays out over procurement cycles rather than as an immediate demand shock. Expect winners to be firms already positioned to supply defence capacity and outsourced healthcare services; conversely, fragile early-stage medtech and university spinouts that rely on grant bridges face a multi-quarter financing cliff as non-dilutive capital dries up.

A second-order fiscal consequence is fiscal substitution by provinces and NGOs: provinces will likely absorb some frontline services (mental health, dental access, training) to avoid political blowback, which drives provincial short-term deficits and incremental provincial bond issuance. That implies upward pressure on provincial yields relative to federal paper over the next 6–24 months and forces banks to re-price provincial credit exposure — a slow-moving credit trade rather than an equity event.

Research and international collaboration retrenchment materially increases commercialisation risk for small Canadian AI and biotech developers who counted on Horizon/European funding corridors; this raises acquisition arbitrage opportunities for global tech and pharma players seeking inexpensive IP. Expect a two-tier outcome: a handful of acquirers with balance sheets scoop up distressed IP/assets within 12–36 months, while many small caps face dilution or insolvency in the nearer term.

Key Decisions for Investors

• Long CAE (CAE.TO / CAE US), 6–18 month horizon: defence procurement cycles and training/equipment spending are sticky and underwritten by government budgets; target +25% with a 12% stop-loss — execution/program delay risk is the main downside.
• Pair trade: Long TELUS (T.TO / TU) + Long SUN LIFE (SLF.TO / SLF), 9–15 month horizon — benefit from outsized private-pay healthcare and supplemental insurance uptake as public programs shrink. Position size: 3–5% each of risk budget; upside 15–30% if adoption accelerates, downside limited to ~10–15% from rate sensitivity and integration execution.
• Tactical short / hedge: buy put spread on a basket of small-cap Canadian life-sciences / AI names (or use a small-cap healthcare ETF if available), 3–12 month tenor — hedge against grant withdrawal and funding cliff. Cost-limited put spreads cap premium outlay while protecting against a 30–50% fall in the cohort.
• Fixed income relative value: increase short exposure to provincials vs long federal paper over 6–24 months (use futures or provincial bond ETFs where liquid) — expect 25–75bps widening of provincial spreads in a stress scenario. Size conservatively and monitor provincial budget announcements for reversals.